Immunoassay

Plasma pTau181 in combination with ApoE4 assays registered a high degree of accuracy in ruling out patients with a low probability of amyloid pathology in the early stages of Alzheimer’s disease, according to a poster presentation at CTAD.

Earlier this year, the FDA granted breakthrough device designation to Quanterix for its blood-based diagnostic assay to aid in the diagnosis of Alzheimer’s disease.

The FDA has granted breakthrough device designation to a phospho-tau 217 blood-based biomarker to assist in the diagnosis of Alzheimer’s disease, according to the manufacturer.

Verséa Ophthalmics announced the distribution of its T-POC Total IgE Immunoassay Kit, a tear-based point-of-care test for the diagnosis and management of ocular surface disease.

At-home medical testing, ranging from cancer screening to COVID-19 detection, may be transforming health care, but some direct-to-consumer hormone test kits have raised red flags for endocrinologists.